[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342621-105":59,"doc-detail-342621-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","c-rel-is-a-novel-oncogene-in-lung-squamous-cell-carcinoma-research-paper","c-Rel is a Novel Oncogene in Lung Squamous Cell Carcinoma - Research Paper","","Lung squamous cell carcinoma (LUSC) represents roughly a quarter to a third of lung cancers, yet targeted options remain limited, motivating the search for new oncogenes driving LUSC growth. REL was identified as a highly amplified oncogene, with REL expression linked to poor patient prognosis. c-Rel knockdown reduced LUSC proliferation and migration, suppressing the NFκB pathway via blocking IκB phosphorylation, and inhibiting tumor growth in orthotopic xenografts and precision-cut tumor slices.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/c-rel-is-a-novel-oncogene-in-lung-squamous-cell-carcinoma-research-paper/342621/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/c-rel-is-a-novel-oncogene-in-lung-squamous-cell-carcinoma-research-paper/342621.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in lung squamous cell carcinoma (LUSC)?","Question",{"text":112,"@type":113},"LUSC has limited targeted therapies, so the study aims to identify new oncogenes that can serve as therapeutic targets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study identify REL as relevant to LUSC?",{"text":117,"@type":113},"REL was identified through screening for oncogenes highly amplified in human LUSC, and its expression correlated with poor prognosis.",{"name":119,"@type":110,"acceptedAnswer":120},"What happens to LUSC cells and tumors when c-Rel is inhibited?",{"text":121,"@type":113},"c-Rel knockdown or pharmacologic inhibition decreases cell proliferation and migration, impairs cancer cell growth, and suppresses the NFκB pathway by blocking IκB phosphorylation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342621,1790645281,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Ivyspring  \nInternational Publisher  \nJournal of Cancer  \n2024; 15(8): 2329-2339. doi: 10.7150/jca.93766  \nResearch Paper  \nc-Rel is a Novel Oncogene in Lung Squamous Cell Carcinoma Regulating Cell Proliferation and Migration  \nRenru Luo1, Qiongyu Liu1, Zheyu Hu1, Wanqin Dai1, Shuwei Huang3, Jianjiang Xie2, Shuquan Wei2􀀍, Chuwen Lin1􀀍  \n1. Department of histology and embryology, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.  \n2. Department of Pulmonary and Critical Care Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.  \n3. School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.  \n􀀍 Corresponding authors: [linchw8@mail.sysu.edu.cn](linchw8@mail.sysu.edu.cn) (C.L.); [eyweishuquan@scut.edu.cn](eyweishuquan@scut.edu.cn) (S.W.) .  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [http://ivyspring.com/terms](http://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2023.12.31; Accepted: 2024.02.12; Published: 2024.03.04  \nAbstract  \nLung squamous cell carcinoma (LUSC) accounts for approximately 25% to 30% of lung cancers, but largely no targeted therapy is available against it, calling for identification of new oncogenes in LUSC growth for new therapeutic targets. In this study, REL was identified through a screening for oncogenes that are highly amplified in human LUSC. Its expression was associated with poor prognosis in LUSC patients. Furthermore, knockdown of c-Rel in LUSC cell lines lead to significant decrease in cell proliferation and migration. Mechanistically, c-Rel knockdown suppressed NFκB pathway by blocking phosphorylation of IκB. Consistently, pharmaceutic inhibition of c-Rel also. In orthotopic xenograft lung cancer mouse model, c-Rel knockdown inhibited the tumor growth. Cancer cell proliferation and epithelial-mesenchymal-transition (EMT) of the tumors were impaired by c-Rel knockdown. Finally, it’s confirmed in precision-cut tumor slices of LUSC that deletion of c-Rel inhibits the NFκB pathway and cancer cell growth. Accordingly, we hypothesize that c-Rel promotes the activation of the NFκB pathway by promoting the phosphorylation of IκB in LUSC. Our study reveals REL as a novel LUSC oncogene and provides new insights into the molecular regulation of LUSC, which will provide new therapeutic targets for the treatment of squamous lung cancer.  \nKeywords: c-Rel; REL; NFκB pathway; LUSC.  \n1. Introduction  \nLung squamous cell carcinoma (LUSC) is a subtype of non-small cell lung cancer (NSCLC) that accounts for approximately 30% of all lung cancersand contributes to over 400,000 deaths globally per year[1] . Although targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors have exhibited efficacy against lung adenocarcinoma, there are no first-line targeted therapies available for LUSC [2] . Consequently, the current 5-year survival rate for LUSC is lower than 20%[3] . Thus, there is an urgent need to identify new oncogenes that promotes LUSC growth, which are ideal candidates for therapeutic targets against LUSC.  \nThe nuclear factor-κB (NFκB) family comprises a group of dimeric transcription factors including RelA/p65, RelB, c-Rel, p50/p105, and p52/p100,  \nwhich exhibit both shared and divergent biological functions. NFκB complex usually exist in an inactive state bound to inhibitory proteins called inhibitors of NFκB (IκBs)[4] . Upon activation, IκB undergoes phosphorylation and rapid degradation, allowing the translocation of NFκB to the nucleus, where it elicits genes that controls multiple processes involved in cancer pathogenesis including proliferation, apoptosis, angiogenesis, and metastasis [5] . Beside a well-established","cbCaisHFKbORXN6O","https://ap.wps.com/l/cbCaisHFKbORXN6O","pdf",4581152,11,"English","# Introduction\n## NFκB signaling and cancer context\n## c-Rel/REL biology and rationale for targeting in LUSC","[{\"question\":\"What problem does the study address in lung squamous cell carcinoma (LUSC)?\",\"answer\":\"LUSC has limited targeted therapies, so the study aims to identify new oncogenes that can serve as therapeutic targets.\"},{\"question\":\"How did the study identify REL as relevant to LUSC?\",\"answer\":\"REL was identified through screening for oncogenes highly amplified in human LUSC, and its expression correlated with poor prognosis.\"},{\"question\":\"What happens to LUSC cells and tumors when c-Rel is inhibited?\",\"answer\":\"c-Rel knockdown or pharmacologic inhibition decreases cell proliferation and migration, impairs cancer cell growth, and suppresses the NFκB pathway by blocking IκB phosphorylation.\"}]","c-Rel is a Novel Oncogene in Lung Squamous Cell Carcinoma - Research Paper | PDF",1790047428,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33ac9873fa66a9f9e6544bd3e498f8a1.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6d3044b08bb4543f981aa0cd27c880c.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6ea4c7666891b5731454283d6909945.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59e1e56fc53515d36a517d875cd1f437.webp",980,1268]